Bridgewater Associates LP Boosts Stake in BioNTech SE (NASDAQ:BNTX)

Bridgewater Associates LP increased its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 257.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,277 shares of the company's stock after buying an additional 14,604 shares during the quarter. Bridgewater Associates LP's holdings in BioNTech were worth $2,311,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of BNTX. State Street Corp increased its holdings in BioNTech by 2.0% in the 3rd quarter. State Street Corp now owns 155,867 shares of the company's stock worth $18,512,000 after buying an additional 3,014 shares during the period. Exome Asset Management LLC acquired a new position in BioNTech in the 3rd quarter worth approximately $4,104,000. GAMMA Investing LLC boosted its position in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares in the last quarter. Retireful LLC purchased a new stake in BioNTech in the 4th quarter worth approximately $260,000. Finally, Atomi Financial Group Inc. boosted its position in BioNTech by 6.7% in the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after purchasing an additional 229 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on BNTX shares. HC Wainwright lowered their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Citigroup started coverage on BioNTech in a research report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective on the stock. BMO Capital Markets increased their target price on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Morgan Stanley decreased their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Price Performance

BioNTech stock traded up $1.96 during mid-day trading on Thursday, reaching $116.79. The company had a trading volume of 711,170 shares, compared to its average volume of 867,635. The stock's 50-day simple moving average is $102.13 and its 200-day simple moving average is $110.78. The company has a market capitalization of $28.03 billion, a P/E ratio of -55.64 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.90 EPS. On average, equities analysts predict that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.